Risks and Benefits of Prostate Cancer Screening: A Review

What is it about?

The study analyzed the evidence on the relative harms and benefits of PSA-based screening and diagnostic pathways in men aged 50 or older, those at higher risk due to ethnicity, and those with a family history. Twenty-eight articles were selected from six trials, including the Göteborg trial. PSA-based screening led to increased detection of low-grade cancer and reduced advanced/metastatic disease but had contradictory effects on prostate cancer mortality. Screening men aged 50-55 reduced the risk of prostate cancer mortality in a subanalysis of an 18-year follow-up study and in a 17-year cohort study from the main Göteborg trial. However, there was a lack of strong evidence on the harms and benefits of PSA screening by socio-clinical risk factors. The review recommends further research to understand the long-term impact of screening on high-risk populations in the current diagnostic setting.

Featured Image

Why is it important?

This research is important because it provides an analysis of the latest evidence on the relative harms and benefits of screening and diagnostic pathways for prostate cancer, specifically for men aged 50 years or older, men whose ethnicity places them at higher risk, and men with a family history. The research examines the impact of PSA-based screening on the detection of low-grade cancer, advanced/metastatic disease, and prostate cancer-specific mortality. Understanding the benefits and harms of PSA screening is crucial for guiding shared decision-making in clinical practice and identifying areas where further research is needed. Key Takeaways: 1. PSA-based screening leads to increased detection of low-grade cancer and a reduction in advanced/metastatic disease but has contradictory effects on prostate cancer-specific mortality. 2. Screening men from a relatively young age (50-55) can reduce the risk of prostate cancer-specific mortality in subanalyses of long-term follow-up studies. 3. Men with a family history who are screened may have a reduced risk of prostate cancer-specific mortality, according to one analysis from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. 4. The research found a lack of strong evidence on the harms and benefits of PSA screening by socio-clinical risk factors and suggests further research is required to understand the long-term impact of screening on high-risk populations in the current diagnostic setting.